9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Estimated reading time: < 1 min

Condition: Adult Anaplastic Astrocytoma

Estimated Enrollment: 75

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Maximum tolerated dose (MTD) of OSI-774 determined by dose-limiting toxicities,  ,  ,

Interventions: erlotinib hydrochloride, laboratory biomarker analysis

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: July 2007

Completion Date:

Last  Posted Date: January 16, 2013

Location: Cancer and Leukemia Group B, Chicago, Illinois, United States

Website Link: https://ClinicalTrials.gov/show/NCT00030498

Was this article helpful?
Dislike 0